Autres domaines


Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects - 27/10/20

Doi : 10.1016/j.biopha.2020.110641 
Liu-Cheng Li a, 1, Zhi-Hui Zhang b, c, 1, Wen-Cheng Zhou d, e, 1, Jie Chen a, Hua-Qian Jin a, Hong-Mei Fang a, Qin Chen a, Ye-Cheng Jin a, , Jiao Qu f, , Lian-Di Kan a,
a Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, PR China 
b Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, PR China 
c Shanghai TCM-Integrated Institute of Vascular Anomalies, Shanghai, 200082, PR China 
d Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, 310018, PR China 
e Department of Pharmacy, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310018, PR China 
f State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, Nanjing, 210023, PR China 

Corresponding authors.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract

El texto completo de este artículo está disponible en PDF.


COVID-19 has led to serious death and lacks treatment strategies.
Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection.
Lianhua Qingwen has antiviral, anti-inflammatory and immunoregulatory activities.
Lianhua Qingwen combined with conventional treatment obviously improved COVID-19.
Lianhua Qingwen can be a complementary strategy for treating COVID-19.

El texto completo de este artículo está disponible en PDF.



An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 2002–2003 in China. Recent data also showed that LHQW played a vigorous role in COVID-19 treatment.


This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19.

Study design and method

The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. The search keywords for screening the literature information were “virus”, “COVID-19”, or “SARS-CoV-2”, and “Lianhua Qingwen”. The documents were filtered and summarized for final evaluation.


The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. Impressively, LHQW in conjunction with conventional treatment could significantly improve COVID-19 patients as a synergetic strategy. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function.


Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. Nevertheless, imperious researches should be conducted to clarify the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19 by means of well designed randomized controlled trials.

El texto completo de este artículo está disponible en PDF.


Keywords : Coronavirus, SARS-CoV-2, Lianhua Qingwen, Antiviral activity, Complementary strategy


© 2020  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir

    Exportación citas

  • Fichero

  • Contenido

Vol 130

Artículo 110641- octobre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatment
  • Fan Yang, Hengwen Chen, Yonghong Gao, Na An, Xinye Li, Xiandu Pan, Xinyu Yang, Li Tian, Jiahao Sun, Xingjiang Xiong, Yanwei Xing
| Artículo siguiente Artículo siguiente
  • How to overcome the side effects of tumor immunotherapy
  • Shang Li, Zhibi Zhang, Wing-Fu Lai, Liao Cui, Xiao Zhu

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta

Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.